#Germany #Düsseldorf #Protein Design #LenioBio #AffinityAI

Revolutionizing Protein Discovery with AI and Cell-Free Expression

LenioBio GmbH, a groundbreaking biotechnology firm, recently announced a strategic partnership with the Danish start-up AffinityAI, known for their innovative AI-driven protein design. This collaboration aims to radically enhance the discovery and optimization of complex proteins, a crucial area in drug development and biomedical research.

At the heart of this partnership lies LenioBio's proprietary cell-free protein expression system, ALiCE®, and AffinityAI's advanced design platform known as Designerbodies™. Together, these technologies promise to accelerate the previously laborious process of protein discovery, making it significantly faster and more efficient. Traditionally, the steps required to design, test, and refine protein sequences could take weeks or even months. However, with the integration of AI-driven design and high-throughput expression, researchers can now see results in mere days.

AffinityAI's capabilities focus on generating novel stable protein sequences that can have high binding affinities to specific targets. Their Designerbodies™ are not just conventional antibodies; they are carefully designed to have predetermined binding sites, which enhances precision and control in therapeutic applications. The challenge that many researchers face with traditional methods is the time it takes to validate these sequences. With LenioBio's ALiCE®, proteins can be expressed quickly and in scalable amounts, bypassing the inherent limitations linked to using live cells for protein production.

"We have fundamentally reinvented cell-free protein expression to unlock the full potential of AI-driven protein design," stated André Goerke, CEO of LenioBio. The synergy created by this partnership allows for a more agile research pipeline that can produce therapeutic proteins with unprecedented speed and accuracy.

The collaboration between LenioBio and AffinityAI is set to streamline the research and development process drastically. The rapid feedback cycles facilitated by this integration mean that researchers can conduct iterative testing and optimization in real-time, increasing the likelihood of success in drug development and biomedical innovations.

Additionally, Timothy P. Jenkins, head of data science at AffinityAI, expressed that their approach aligns perfectly with LenioBio’s technology. He noted, "Together, we can deliver Designerbodies™ at a higher throughput and with unmatched precision." This approach is not just an incremental improvement; it represents a significant leap forward in how new proteins are discovered and developed for therapeutic use.

As this partnership develops, we can expect to see an influx of innovative protein-based solutions in areas such as drug development, diagnostics, and clinical research. The intersection of biotechnology and artificial intelligence is carving out a new frontier in medical science, one that holds promise for the quicker development of life-saving drugs and treatments.

About LenioBio

LenioBio GmbH was founded in 2016 in Germany and is headquartered in Düsseldorf. The company specializes in cell-free protein expression technologies that enable rapid discovery and scalable production of proteins without relying on living cells. Their platform, ALiCE®, has set a new standard in the field, pushing the boundaries of what is possible in protein engineering.
For more information, visit www.leniobio.com or follow them on LinkedIn.

About AffinityAI

Based in Copenhagen, AffinityAI is a biotechnology company at the forefront of AI-guided protein design. Their Designerbodies™ offer fast and effective solutions for binding specific target epitopes, thereby reducing the time needed for antibody development. They operate on the cutting edge of technology to provide next-generation therapeutic innovations. More information can be found at affinityai.dk.